Mechanically, our study identifies ZLD1039 as a potential anti-fibrotic therapeutic agent that attenuates renal fibrosis by inhibiting EZH2/H3K27me3 and up-regulating LATS1, thereby preventing YAP nuclear translocation (Fig. 7f). This evidence concerns the gene EZH2 and renal fibrosis.